Pure Global AI
NCT06381050Not yet recruiting

The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid Tumors

An Open-label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-7631 for Injection in Patients With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Advanced Solid Tumors
Drug/Device/Intervention
SHR-7631
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Location
Beijing,Guangzhou, China
Timeline & enrollment
Phase
Phase 1
Start date
May 01, 2024
End date
Apr 01, 2027
Enrollment
150 participants
Primary outcome

Maximum tolerated dose (MTD) or maximum administered dose (MAD),Incidence and severity of adverse events (AEs)/serious adverse events (SAEs) (CTCAE v5.0)

Summary

This study is an open-label, phase I clinical trial of SHR-7631 in patients with advanced
 solid tumors. The whole study is divided into three stages: dose escalation, dose expansion
 and efficacy expansion.

ICD-10 classifications
Malignant neoplasm: PrepuceCarcinoma in situ, unspecifiedMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm: Orbit
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06381050
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06381050 through Pure Global AI's free database. This Phase 1 trial is sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. and is currently Not yet recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 150 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.